Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07819214
PHASE2
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Sponsor: University of California, Irvine
View on ClinicalTrials.gov
Summary
This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).
Official title: Epcoritamab as Consolidation Therapy for High-risk Patients With Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-10
Completion Date
2032-10
Last Updated
2026-09-14
Healthy Volunteers
No
Interventions
DRUG
Epcoritamab
Interventional Arm
Locations (1)
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States